Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Vaginal Atrophy 1Uterine Cervical Neoplasms 1Rectal Neoplasms 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Metastatic Breastcancer 1Anus Neoplasms 1

Interventions

Fluorouracil 13Cisplatin 7Radiotherapy 6Specimen Handling 5Mitomycin 5Capecitabine 5pembrolizumab 4dehydroftorafur 4Radiation 4Drug Therapy 4Cetuximab 4Radiotherapy, Intensity-Modulated 3Paclitaxel 3Nivolumab 3Magnetic Resonance Spectroscopy 3Carboplatin 3Biopsy 3tislelizumab 2durvalumab 2aldesleukin 2VGX-3100 2Platinum 2Mitozytrex 2Immune Checkpoint Inhibitors 2Fluorodeoxyglucose F18 21,2-diaminocyclohexaneplatinum II citrate 2toripalimab 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1spartalizumab 1rocakinogene sifuplasmid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Anus Neoplasms × Dehydroepiandrosterone × Clear all
NCT07407647 2026-04-21

Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
25 enrolled
GastrointestinalGynecologic

Anus Neoplasms, Uterine Cervical Neoplasms, Rectal Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡